Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486003 | 0.88 | SCN9A (0.54) | SCN9A | |
| SCHEMBL17473883 | 0.82 | SCN9A (0.63) | SCN9A | |
| SCHEMBL16129844 | 0.82 | SCN9A (0.63) | SCN9A | |
| SCHEMBL17473873 | 0.81 | SCN9A (0.43) | SCN9A | |
| SCHEMBL17473874 | 0.81 | SCN9A (0.43) | SCN9A | |
| SCHEMBL16130052 | 0.81 | SCN9A (0.39) | SCN9A | |
| SCHEMBL17473854 | 0.81 | SCN9A (0.52) | SCN9A | |
| SCHEMBL17473857 | 0.77 | SCN9A (0.47) | SCN9A | |
| SCHEMBL17473859 | 0.77 | SCN9A (0.47) | SCN9A | |
| SCHEMBL16129979 | 0.75 | SCN9A (0.45) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2017-04-06 | — | — | US | disclosed |
| US-9493449-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | PURDUE PHARMA L.P. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | SCN9A 70/4885KMT2A 1142/4885DDB1 4821/4885 |
| US-20160031873-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | SCN9A 79/4885KMT2A 956/4885DDB1 4828/4885 |
| US-20170096421-A1 | Carboxamide Derivatives and Use Thereof | TRPV1, CACNA1A, SCN10A | SCN9A 70/4885KMT2A 1142/4885DDB1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.